U.S. pharma huge copyright scrapped two experimental weight loss tablets last yr—a when-daily pill, lotiglipron, due to elevated liver enzymes and a twice-each day pill, danuglipron, resulting from robust Negative effects—but CEO Albert Bourla has explained the company is set to &ldq